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CASE REPORT
Out-of-field (abscopal) tumor response is a manifestation of 
the systemic effect of radiation and has been documented 
in several tumor types.1 However, clinical reports of absco-
pal effects in non–small-cell lung carcinoma (NSCLC) are 
extremely rare.2 This report describes an instance of apparent 
spontaneous regression of metastases outside of irradiated 
portals in a patient with NSCLC, suggestive of an abscopal 
response.
A 78-year-old woman presented with weight loss 
of 10 kg (17%) over 6 months, with concurrent loss of 
appetite, dry cough, and episodes of exertional dyspnea. 
Staging with fluorodeoxyglucose positron emission tomog-
raphy computed tomography (FDG-PET/CT) revealed a 
left upper lobe T3N0M0 biopsy-proven adenocarcinoma 
measuring 6.9 × 7.4 × 7.5 cm, and a right lower lobe (RLL) 
biopsy-proven synchronous primary adenocarcinoma mea-
suring 1.8 × 1 × 1 cm. The left upper lobe tumor was treated 
with 60 Gy in 30 fractions of radiation therapy, with con-
current carboplatin and paclitaxel. A complete metabolic 
response was achieved at 5 weeks. The patient, subse-
quently, received a single fraction of 26 Gy stereotactic 
ablative radiation therapy (SABR) to the RLL T1 primary 
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FIGURE 1.  Serial PET scans in the patient, focusing on changes in the left upper lobe T3 primary (inset above) and the right 
lower lobe synchronous T1 primary (inset below). PET, positron emission tomography; SABR, stereotactic ablative radiation 
therapy.
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as part of a prospective clinical trial. Serial PET scans were 
performed as per the trial protocol (Figs. 1 and 2). A 14-day 
PET scan revealed increased metabolic activity in the 
RLL lesion suggestive of metabolic flare secondary to 
SABR, and the appearance of a new right adrenal metas-
tasis. A 70-day FDG-PET/CT scan showed ongoing met-
abolic flare in the RLL lesion, a new FDG-avid lesion 
consistent with right adrenal metastasis, and a new FDG-
avid lytic lesion in the right humeral head consistent with 
a bone metastasis.
At this stage, the patient was offered systemic che-
motherapy, which was declined. An FDG-PET/CT scan 
performed 12 months after completion of SABR showed a 
complete metabolic response in all sites of abnormal FDG-
uptake, associated with sclerotic healing in the left humerus 
and reduced tumor mass in the right adrenal. There was sus-
tained ongoing low-grade inflammatory uptake in both lungs 
in the irradiated volumes. A final FDG-PET scan performed 
15 months after SABR, showed ongoing response in all previ-
ous sites but with a new FDG-avid lytic lesion in the left scap-
ula consistent with a solitary osseous metastasis. This lesion 
was to be treated with SABR.
DISCUSSION
Abscopal effects in normal and tumor tissues were first 
described as “an action at a distance from the irradiated vol-
ume but within the same organism.”3 The effect is attributed 
to activation of the systemic immune response. Radiation-
induced inflammation is known to increase antigen presen-
tation, subsequent tumor recognition, and can ultimately, 
enhance the tumor-directed immune response.4 This effect 
may be more pronounced in response to ablative rather than 
conventional dosage or fractionation schedules.5 Our patient 
had a sustained inflammatory metabolic signal in response to 
the single SABR fraction in the context of right adrenal and 
left humeral metastasis. These sites of disease subsequently 
resolved without systemic intervention. We postulate that 
the brisk, sustained inflammatory response in this patient 
resulted in a strong immunogenic response and subsequent 
abscopal regression in the sites of remaining disease. The 
weakness of our observation is that there was no pathologi-
cal confirmation obtained of the metastatic disease, nor any 
correlative blood or tissue samples, which demonstrated a 
positive immunological effect. Abscopal effects secondary 
to SABR have previously been reported in renal cell carci-
noma,6 but to our knowledge, this is the first such report in 
the setting of NSCLC.
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FIGURE 2.  Serial PET scans in the patient, focusing on changes in the left humerus metastasis (inset above) and the right adre-
nal metastasis (inset below). PET, positron emission tomography; SABR, stereotactic ablative radiation therapy.
